學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
The Trials of a Social Entrepreneur: ZiDi, MicroClinic Technologies and Kenyan Healthcare
內容大綱
Physician Moka Lantum was ready to try his hand as a social entrepreneur, aiming to improve healthcare for an underserved population in rural Kenya, where access to clinics was difficult, curable diseases flourished, maternal and child mortality rates were high, and dangerous counterfeit drugs flooded the market. Lantum began to develop a technological solution that could address multiple public sector healthcare problems through a single IT tool, ZiDi, a cloud-based system that could process a wide array of information, from individual patients and their symptoms to drug supplies, the utilization rate of individual clinics, or staff absenteeism. Lantum and a Kenyan partner incorporated MicroClinic Technologies Inc. (MCT), launching ZiDi in August 2012. Lantum's goal for MCT was to demonstrate that ZiDi could improve maternal and child health in rural clinics and dispensaries, and persuade the government to buy it. Over the next two years, ZiDi proved useful, and MCT won endorsements and awards-but no government contract, not even a request for proposal (RFP). By August 2014, the slow pace of government decision-making was threatening MCT's existence. Lantum had to decide: stay the public sector course or diversify into an uncharted market segment with its own unknowns?